B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy

B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy

β2-microglobulin (B2M) and Janus kinases 1 and 2 (JAK1/2) mutations have been suggested as genetic mechanisms of immune evasion for anti-programmed cell death protein 1 (PD-1) therapy. Whether B2M and JAK1/2 lose-of-function mutation can cause primary resistance to anti-PD-1 therapy in colorectal ca...

Full description

Bibliographic Details
Main Authors: Ding, P. (Author), Han, K. (Author), Hou, Z. (Author), Jiang, W. (Author), Li, D. (Author), Li, Y. (Author), Liao, L. (Author), Pan, Z. (Author), Sui, Q. (Author), Tang, J. (Author), Xiao, B. (Author), Zhang, C. (Author), Zhang, L. (Author), Zhang, R. (Author), Zhang, X. (Author), Zhou, C. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items